Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Spesolimab by Boehringer Ingelheim International for Pyoderma Gangrenosum: Likelihood of Approval
Spesolimab is under clinical development by Boehringer Ingelheim International and currently in Phase II for Pyoderma Gangrenosum. According to GlobalData,...
Spesolimab by Boehringer Ingelheim International for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair): Likelihood of Approval
Spesolimab is under clinical development by Boehringer Ingelheim International and currently in Phase III for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo...
Spesolimab by Boehringer Ingelheim International for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair): Likelihood of Approval
Spesolimab is under clinical development by Boehringer Ingelheim International and currently in Phase III for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo...